Once-weekly diabetes drug backed in draft NICE guidance

Once-weekly type-2 diabetes drug exenatide has been recommended for third-line use in draft guidance from NICE.

NICE draft guidance recommends exenatide
NICE draft guidance recommends exenatide

Exenatide prolonged release has been recommended for use with metformin in addition to either a sulphonylurea or a thiazolidinedione. Its use should be restricted to people HbA1c levels above 7.5% and a BMI over 35 or who are unsuitable for insulin therapy, NICE has said.

The draft recommends that long-acting exenatide should only be used for patients unsuitable for triple therapy with any three of: metformin, a sulphonylurea, a thiazolidinedione and a dipeptidyl peptidase-4 inhibitor.

NICE’s draft guidance on long-acting exenatide is open for consultation until 8 November, with final guidance likely to be published in February 2012.

Commenting on the draft decision, Professor Carole Longson, director of the health technology evaluation centre at NICE said: ‘Type-2 diabetes is becoming increasingly more common in adults, so we are pleased to recommend exenatide as a treatment option for some people with the condition.’

Long-acting exenatide is marketed by Eli Lilly as Bydureon suspension for injection.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...